Sensei Biotherapeutics (NASDAQ:FTH) CFO Brian Stephenson Acquires 8,183 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson acquired 8,183 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average cost of $22.13 per share, for a total transaction of $181,089.79. Following the acquisition, the chief financial officer directly owned 8,183 shares of the company’s stock, valued at $181,089.79. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ FTH opened at $24.54 on Thursday. Sensei Biotherapeutics, Inc. has a one year low of $6.32 and a one year high of $36.76.

Key Headlines Impacting Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: CEO Anand Kiran Parikh bought 2,806 shares at $19.76 each, signaling confidence in Sensei Biotherapeutics’ outlook. CEO purchase SEC filing
• Positive Sentiment: CFO Brian C. Stephenson bought 9,230 shares at $24.36 each, a larger insider purchase that can be viewed as a strong vote of confidence from management. CFO purchase SEC filing
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $60 price target, while lifting forecasts across multiple future periods, reinforcing a bullish long-term view of the stock. HC Wainwright research note
• Neutral Sentiment: HC Wainwright’s estimates still call for losses over the next several quarters and years, so the outlook remains highly speculative and dependent on future clinical or operational progress.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a research report on Monday. They set a “buy” rating and a $60.00 price target for the company. BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Finally, Weiss Ratings assumed coverage on Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.